Examining the Impact of the World Health Organization 2022 Guidelines on Evaluation of Biosimilars for Non-Local Comparators in Biosimilar Studies on Middle East and North Africa Member States
Global support and standardization of regulation for biosimilars approval owes much of its legacy to the World Health Organization (WHO), since the first guidance by the organization on the matter was released in 2009. Since then, and with over a decade of research, the 2022 revision provides opport...
Saved in:
Main Authors: | Michael W. Strand (Author), Jonathan H. Watanabe (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Guidelines of research biosimilar drugs
by: R. . Ivanov, et al.
Published: (2014) -
Biosimilars
Published: (2022) -
Biosimilars
by: Emel Bülbül Başkan
Published: (2022) -
Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa
by: Almaaytah A
Published: (2020) -
Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018)